Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Resverlogix Granted Approval of Two China Patents for Cardiovascular Drug

publication date: Apr 7, 2015
Resverlogix Corp. of Canada announced that its lead molecule, RVX-208, a first-in-class, small molecule treatment for cardiovascular disease, was granted two China patent approvals. With the new IP protection, which extends to 2029, Resverlogix will seek to out-license China rights for the clinical stage drug candidate and will present at next week's ChinaBio® Partnering Forum in Shanghai. According to Resverlogix, RVX-208, a BET bromodomain inhibitor, works by transporting plaque from the blood stream to the liver, where it is eliminated from the body. Resverlogix has completed two Phase IIb trials of RVX-208. More details....

Stock Symbol: (TSX: RVX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital